The drug is so effective and now NCCN-endorsed for chemotherapy-induced thrombocytopenia that recruiting patients for a placebo-controlled trial to prove long-term survival benefits is nearly impossible. Patients would refuse the risk of receiving a placebo when an effective treatment is available off-study.
The RECITE trial proved romiplostim effectively maintains platelet counts, allowing patients to receive their full, intended chemotherapy dose (relative dose intensity). However, the critical link between maintaining this dose and actually improving progression-free or overall survival has not yet been established.
Despite lacking specific FDA approval for chemotherapy-induced thrombocytopenia (CIT), romiplostim is widely used and reimbursed. This is because the influential National Comprehensive Cancer Network (NCCN) endorsed its use based on earlier Phase II data, demonstrating how clinical guidelines can establish standard of care.
Since a long-term, randomized trial for romiplostim is impractical, the proposed next step is to conduct large-scale, retrospective epidemiological studies. This approach would compare outcomes in matched populations of patients who did and did not receive the drug, representing a pragmatic shift in research strategy.